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Endothelin ETA Receptor Blockade With Darusentan
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This study investigated whether intrarenal endothelin-1
(ET-1) contributes to sodium excretion in aged rats.
Metabolic function studies were performed in male
Wistar rats (3 and 24 months) treated with placebo or
the orally active ETA receptor antagonist darusentan
(20mg/kg/d) for 4 weeks. Mean arterial pressure was
measured using an intra-arterial catheter. Electrolytes,
aldosterone levels, renin activity, and angiotensin con-
verting enzyme activity were determined in plasma, and
mRNA expression of epithelial sodium channel (ENaC)
and Na+, K+-ATPase subunits was measured in the
renal cortex and medulla. Aging was associated with a
marked decrease in urinary excretion of sodium, chloride,
and potassium (all P<0.001) as well as renin activity
(P<0.05), but had no signiﬁcant eﬀect on gene expres-
sion of ENaC or Na+, K+-ATPase subunits. In aged
rats, darusentan treatment increased ion excretion
(P<0.05), reduced cortical gene expression of aENaC
and a1-Na
+, K+-ATPase (both P<0.05), and increased
plasma aldosterone levels (P<0.01). These data demon-
strate a decrease of sodium and potassium excretion in
aged rats, changes that are partly sensitive to ETA
receptor blockade. Treatment with darusentan also
reduced cortical expression of aENaC and a1-Na
+,
K+-ATPase and increased plasma aldosterone levels
independently of blood pressure, electrolytes, renin
activity, or angiotensin converting enzyme activity. These
ﬁndings may provide new pathogenetic links between
aging and sodium sensitivity.
Key Words: gene expression, hypertension-Na/K-pump-Na
channel
(J Cardiovasc Pharmacol
TM
2006;47:456–462)
Endothelin-1
1–21 (ET-1) is one of the most potent
vasoconstrictor peptides known1,2 and the predomi-
nant isoform of the ET peptide family. It has been
implicated in the pathogenesis of cardiovascular and renal
disease (reviewed in Refs. 3, 4), including salt-sensitive
hypertension.5 Two human receptors for ET-1 have been
identiﬁed and cloned: the ETA receptor which is located
on vascular smooth muscle cells mediating vasoconstric-
tion, and the ETB receptor which is predominantly
located on endothelial cells mediating vasodilation
(reviewed in Ref. 3). A number of orally active
antagonists for these receptors have been developed and
experimental studies demonstrated their beneﬁcial eﬀect
in diﬀerent models of cardiovascular and renal disease,
partly or completely independent of blood pressure.6–11
Aging is an important and independent risk factor
for renal and cardiovascular disease.12 In the aging
kidney, changes occur with regard to glomerular structure
and function, blood ﬂow, and excretion of ions and drugs
(reviewed in Ref. 13). We14,15 and others16 have
previously shown that renal ET-1 expression increases
in the aging kidney and that it contributes to glomerulo-
sclerosis.11 Although endothelins are known to regulate
several functions in renal physiology, including vascular
tone, cell proliferation, and diuresis (reviewed in Ref. 4),
its role for ion excretion with aging is still unclear.
Impairment in sodium excretion (or increased sodium
reabsorption, respectively) may result in elevated blood
pressure frequently deﬁned as ‘‘salt-sensitive’’ hyperten-
sion; however, the underlying mechanisms of salt
sensitivity are not fully understood.17 The incidence of
sodium sensitivity increases with age18 and is associated
with a high risk for end-organ damage and cardiovascular
events.19 Moreover, there is evidence for a relationship
between sodium sensitivity and cardiovascular mortality
in normotensive patients even before the onset of
hypertension.20
The objective of the present study was therefore to
test the hypothesis whether intrarenal ET-1 contributes to
the regulation of ion excretion in aged rats by using theCopyright r 2006 by Lippincott Williams & Wilkins
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orally active ETA receptor antagonist darusentan. As
sodium reabsorption in the distal nephron primarily
occurs via the apical epithelial sodium channel (ENaC)
maintained by the basolateral Na+, K+-ATPase, the
eﬀects of aging and/or ETA receptor blockade on the
expression of these genes in the renal cortex and medulla
were also investigated.
METHODS
Animal Studies
Male Wistar rats (IFFA Credo/Charles River,
L-Arbesle, France) were subjected to 24-hour metabolic
studies at the age of 2 and 23 months as described.11
Brieﬂy, animals were placed in individual metabolic cages
and urine was collected after a 24-hour acclimatization
period. Urine was centrifuged, stored at  801C, and
determination of urinary parameters was performed on
an autoanalyzer (model 917, Roche/Hitachi, Basel,
Switzerland). Animals were randomized to treatment for
4 weeks with or without the orally active ETA receptor
antagonist darusentan (formerly LU135252, 182-fold
selectivity for ETA over ETB; 20mg/kg/d, Knoll AG,
Ludwigshafen, Germany; n=8 to 9 per group) in
drinking water as described.11 Food intake (standard
rodent chow) and water intake was monitored through-
out the study. At the end of treatment, metabolic cage
studies were repeated. Animals were anesthetized (thio-
pental, 50mg/kg body weight, IP), venous blood samples
were obtained (centrifuged at 41C and 5000 rpm for
15min and plasma stored at  801C), and animals
were killed by exsanguination. Kidneys were removed,
decapsulated, immediately snap-frozen in liquid nitrogen,
and kept at  801C. Mean arterial blood pressure
measurements were performed using an intra-arterial
catheter as described.11 Experiments were in accordance
with the Guide for the Care and Use of Laboratory
Animals published by the NIH.
Measurement of Sodium, Chloride, and
Potassium in Plasma
Electrolytes were measured using a Cobas Integra
800 (Roche Diagnostics, Rotkreuz, Switzerland) by
standard procedures recommended by the International
Federation of Clinical Chemistry.21
Measurement of Aldosterone Levels, Renin
Activity, and Angiotensin Converting Enzyme
Activity in Plasma
Plasma aldosterone levels (nmol/L) were quantiﬁed
using a direct radioimmunoassay (RIA) with a speciﬁc
antiserum and 3H-labeled aldosterone as previously
described.22 Plasma renin activity (mg/L/h) was quantiﬁed
by RIA (GammaCoat, DiaSorin Inc, MN), which
involves an initial incubation of plasma to generate
angiotensin I, followed by the quantiﬁcation of angio-
tensin I by RIA. Angiotensin converting enzyme (ACE)
activity (U/L) was quantiﬁed by a radio-enzymatic assay
(Bu¨hlmann Laboratories AG, Allschwil, Switzerland).
Renal Gene Expression Studies
Renal cortex and medulla were separated as
described previously.9 Total RNA was extracted from
tissues using the silica-based RNeasy Minikit (Qiagen,
Hilden, Germany). Purity of RNA was controlled by
RT( ) reactions (PCR with nontranscribed RNA).
RNA was reverse-transcribed with the Omniscript RT
kit (Qiagen, Hilden, Germany). Real-time quantitative
PCR was used as described11 to quantify expression of
genes encoding rat aENaC, bENaC, gENaC, a1-Na
+,
K+-ATPase, and g-Na+, K+-ATPase. For standardiza-
tion, expression of the gene encoding for rat 18s RNA
was used (house-keeping gene). The following primers
were used: 50-ACC GCT TCC ATT ACA TCA ACA
TTC-30 (forward), 50-GTG GAA CTT GGA ATA ATT
CGC CTG-30 (reverse) for ampliﬁcation of an aENaC
speciﬁc cDNA fragment; 5´-GCC ATG TGG TTC CTG
CTC AC-30 (forward), 50-GCT CAG GTA GGT CTG
GAT GAA GA-30 (reverse) for ampliﬁcation of a bENaC
speciﬁc cDNA fragment; 50-CAA AGC CAA GGA TTG
TTG GGC-30 (forward), 50-AGG TCA TCG TCC GTA
TCC AGA G-30 (reverse) for ampliﬁcation of a gENaC
speciﬁc cDNA fragment; 50-TGG GCA TTA TCT CAG
AAG GTA ACG-30 (forward), 50-TCA CCT GGT TCA
CTG GAA TGT TG-30 (reverse) for ampliﬁcation of
an a1-Na
+, K+-ATPase speciﬁc cDNA fragment and
50-AAA CCG TCC GCA AAG GAG GC-30 (forward),
50-CCG TCA CAG CTC ATC TTC ATT GAC-30
(reverse) for ampliﬁcation of a g-Na+, K+-ATPase
speciﬁc cDNA fragment, and rat 18s ribosomal RNA
(primers 50-ACA CGG ACA GGA TTG ACA GAT TG-
30 (forward), 50-CAG ACA AAT CGC TCC ACC AAC
T-30 (reverse). Two-step PCR was performed with an iQ
SYBR Supermix PCR kit (Bio-Rad, Switzerland) as
follows: activation of the hot start Taq polymerase for 3
minutes (951C), followed by 45 cycles of denaturation at
951C for 15 seconds (step 1), and annealing and extension
at 601C for 1 minute (step 2). Fluorescence was detected
at the end of each extension step. Identity and speciﬁcity
of amplicons were conﬁrmed by agarose gel electrophor-
esis, melting curve analysis, and sequencing (Microsynth,
Balgach, Switzerland). Gene expression was calculated
using the 2DDCT method.11
Statistical Analysis
Data are given as mean±SEM and n equals the
number of animals. For multiple comparisons, results
were analyzed using ANOVA, followed by Bonferroni’s
correction. For comparisons between 2 values, the
unpaired or paired t test were used when appropriate. A
P value <0.05 was considered signiﬁcant.
RESULTS
Physiologic Parameters
During the study period of 4 weeks, body weight
increased in young but not in old rats (P<0.001,
Table 1). Aging was associated with a decrease in food
intake (31±5 vs. 54±1g/kg/d, P<0.001 vs. young),
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water intake, and urine excretion (both P<0.001 vs.
young, Table 1) whereas mean arterial pressure was not
aﬀected by aging (ns, Table 1). Darusentan treatment had
no eﬀect on food intake (56±2 vs. 54±1 and 38±4 vs.
31±5g/kg/d, ns), body weight, water intake, urine
excretion, and mean arterial pressure in young or aged
animals (all ns, Table 1).
Renal Function Studies
In aged animals, a decrease in the absolute excretion
of sodium ions (2.6±0.2 vs. 5.8±0.3mmol/kg/24 h),
chloride ions (2.2±0.2 vs. 6.0±0.2mmol/kg/24 h), and
potassium ions was observed (5.5±0.4 vs. 12.5±
0.3mmol/kg/24 h, all P<0.001 vs. young, Figs. 1A–C,
left panels). In aged but not in young rats, darusentan
treatment increased the excretion of sodium (+35%),
chloride (+46%), and potassium (+27%, all P<0.05 vs.
untreated, Figs. 1A–C, left panels). Changes in ion
excretion before and after darusentan treatment were
also observed intraindividually in aged rats: absolute
excretion of sodium increased from 3.0±0.3 to 3.5±
0.2mmol/kg/24 h, chloride from 2.6±0.3 to 3.3±0.3
mmol/kg/24h, and potassium from 6.1±0.4 to 7.0±
0.4mmol/kg/24 h (all P<0.01, paired t test, Figs. 1A–C,
right panels).
Plasma Levels of Sodium, Chloride, and
Potassium
Aging or treatment with darusentan had no eﬀect
on plasma electrolytes (all ns, Table 2).
Plasma Aldosterone Levels, Renin Activity, and
ACE Activity
Aldosterone plasma levels were similar in untreated
animals. However, darusentan treatment increased plas-
ma aldosterone levels by 43% in aged but not in young
rats (from 2.3±0.1 to 3.3±0.3 nmol/L, P<0.01 vs.
untreated, Fig. 2A). Plasma renin activity was reduced
by more than 75% with aging (5.3±1.3 vs. 22.6±3.7 mg/
L/h, P<0.05, Fig. 2B) and unaﬀected by treatment. ACE
activity was unaﬀected by aging or darusentan treatment
(Fig. 2C).
Renal Gene Expression of ENaC- and Na+,
K+-ATPase Subunits
Marked diﬀerences with regard to absolute expres-
sion levels between subunits of Na+, K+-ATPase and
ENaC were noted, with expression being highest for
a1-Na
+, K+-ATPase and aENaC (data not shown).
Expression of g-Na+, K+-ATPase was higher in the
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FIGURE 1. Effects of aging and darusentan treatment on
absolute urinary excretion of sodium (A), chloride (B), and
potassium (C). Right panels: paired data of individual animals.
Effects of darusentan treatment on absolute urinary excretion
of sodium (A), chloride (B), and potassium (C) in aged
rats after 4 weeks. Y indicates young control; YD, young
darusentan; O, old control; OD, old darusentan. Every column
represents n = 8 to 9 animals. Data are means ± SEM.
*P < 0.001 versus young, wP < 0.05 versus old control,
zP < 0.01 versus week 0.
TABLE 1. Physiological Parameters
Age
Young Old
Treatment Control Darusentan Control Darusentan
Body weight, week 0 (g) 318±3 322±4 652±24* 636±18*
Body weight, week 4 (g) 436±5w 452±8w 631±36* 643±18*
Water intake (g/kg/d) 72±4 71±3 35±5* 39±5*
Urine excretion (g/kg/d) 36±3 30±3 18±2* 23±2
Mean arterial pressure
(mm Hg)
102±3 101±2 101±1 103±3
Eﬀects of aging and darusentan treatment on body weight, water intake, urine
excretion, and mean arterial pressure. Data are means±SEM, n=8 to 9 animals.
*P<0.001 versus young.
wP<0.001 versus week 0.
TABLE 2. Plasma Electrolytes
Age
Young Old
Treatment Control Darusentan Control Darusentan
Sodium (mmol/L) 146±0 147±1 147±1 148±1
Chloride (mmol/L) 106±1 106±1 107±1 109±1
Potassium (mmol/L) 4.6±0.3 4.9±0.2 4.1±0.3 4.6±0.2
Eﬀects of aging and darusentan treatment on plasma values of sodium,
chloride, and potassium. Data are means±SEM, n=4 to 7 animals.
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medulla than in the cortex of young animals (P<0.05,
data not shown), whereas the other subunits showed
comparable expression levels between the medulla and
cortex. Surprisingly, aging per se had no signiﬁcant eﬀect
on gene expression; however, there was a trend toward
higher expression of aENaC in the medulla of aged
animals (P=0.15 vs. young, Fig. 3A, right panel).
Darusentan treatment reduced gene expression of aENaC
( 72%, P<0.05, Fig. 3A, left panel) and a1-Na+, K+-
ATPase in the cortex of old rats ( 50%, P<0.05,
Fig. 3B, left panel).
DISCUSSION
This study demonstrates that aging leads to a
marked reduction of sodium, potassium, and chloride
excretion in otherwise healthy and normotensive rats,
which was reversed in part after treatment with an orally
active endothelin receptor antagonist. As no eﬀects were
observed in young animals, these data suggest a role for
the ETA receptor contributing to renal excretory function
in the aged kidney. The results further show that ETA
receptor blockade reduces cortical aENaC as well as
a1-Na
+, K+-ATPase expression and increases plasma
aldosterone levels in aged rats only. These eﬀects occured
independently of mean arterial pressure, plasma electro-
lytes, or activity of circulating renin and ACE.
In previous studies, we have demonstrated that
renal ET-1 expression increases in aged rodents14,15
and that ET-1 contributes to age-dependent glomerulo-
sclerosis.11 Studies in ET-transgenic mice showed age-
dependent glomerulosclerosis, interstitial ﬁbrosis, and
decreased creatinine clearance and/or glomerular ﬁltra-
tion rate, respectively.23,24 Interestingly, ET-transgenic
animals do not spontaneously develop hypertension;
however, one of the transgenic lines described by Hocher
et al23 was characterized by high intrarenal ET-1
expression and also showed a marked decrease in sodium
excretion with aging. The ﬁnding that sodium excretion
decreases with aging might have been partly inﬂuenced by
lower food intake in aged rats. However, and in line with
the ﬁndings of the present study, a marked decrease in
sodium excretion was observed in aged females of the
same strain.25,26 As one of these studies was performed
after an overnight fasting period,26 and changes in
sodium homeostasis in the rat require only hours,27 a
decreased ion excretion in aging rats is unlikely to be
determined by food intake alone. Renal aging has been
associated with a failure to conserve sodium and therefore
potential ‘‘salt-wasting;’’13 interestingly, salt-sensitive
hypertension in humans is also associated with impaired
sodium excretion and suppressed renin levels.17 In this
context it is interesting to note that decreases in urinary
potassium excretion, as seen in our study, have been most
recently suggested to play a role in sodium sensitivity
in blacks.28
Compatible with our ﬁndings that show improved
sodium excretion after ETA receptor blockade, ET-1
infusion decreases sodium excretion in healthy volunteers
via activation of ETA receptors.
29,30 Two previous animal
studies have used the nonselective ET receptor antagonist
bosentan acutely to determine kidney function.
Consistent with our observations, Greenfeld et al31
reported an increased excretion of sodium in Sprague-
Dawley rats of diﬀerent age groups after blockade of
endogenous ET-1, whereas in a study performed in
Wistar rats by Hocher et al32 bosentan decreased sodium
excretion on top of coinfusion of ET-1. In these
studies31,32 and in our previous study,11 ET receptor
blockade had no eﬀect on blood pressure, glomerular
ﬁltration rate, renal blood ﬂow, or urine ﬂow. Indeed, the
data of the present study indicate that blocking endogen-
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ous ETA receptor activation was unrelated to urine
excretion; additionally, treatment had no eﬀect on body
weight or food and water intake. This is in line with 2
studies also reporting no eﬀect of ET receptor blockade
on food and water intake or urine volume in adult
Sprague-Dawley rats.33,34 However, we cannot exclude
the possibility that additional, nonrenal mechanisms such
as eﬀects of ET on the central nervous system were also
involved in the natriuretic eﬀects of darusentan.35
With regard to the role of ET-1 for sodium
homeostasis, the data available up to now have been
conﬂicting. In vivo studies using systemic infusion suggest
that ET-1 may decrease or increase sodium excretion
through ENaC activation depending on the dose of ET-1
(reviewed in Ref. 4). A bimodal function of ET-1 for
ENaC regulation in distal nephron cells in vitro was also
demonstrated by Gallego and Ling.36 These investigators
found that nanomolar concentrations of ET-1 activate
ENaC via the ETA receptor, resulting in sodium
reabsorption in the collecting duct, whereas lower
concentrations inhibit ENaC by ETB receptor activation.
Such a mechanism could provide a possible explanation
for our in vivo ﬁndings showing that impaired excretion
of sodium chloride was reversed in part after selective
ETA blockade. The data of the present study further
suggest a functional role for endogenous ET-1 in the aged
kidney that may depend on local concentrations of ET-1
peptide. Thus, in the aged kidney increased local levels of
endogenous ET14,37 may promote sodium reabsorption,
whereas blockade of the ETA receptor interferes with
ENaC activation. This notion would also be supported by
the observation that darusentan had no eﬀect in young
rats on any of the parameters investigated. Moreover, we
propose that, during darusentan treatment of aged rats,
an ETB-mediated inhibitory eﬀect on ENaC and sodium
reabsorption becomes activated, as increased intrarenal
levels of the ETB agonists ET-1 and ET-3
14,37 may still
activate the ETB receptor in the presence of selective ETA
receptor blockade. Indeed, studies in ETB receptor-
deﬁcient animals as well as functional studies have
provided substantial evidence supporting a role of this
receptor in salt-sensitivity by regulating sodium excretion
via ENaC.32,38–41 In addition to eﬀects on ENaC,
ET-1 also inhibits Na+, K+-ATPase activity in the
collecting duct42 and thus aﬀects transepithelial sodium
transport.43 Na+, K+-ATPase importantly controls
transepithelial sodium transport and has been localized
in most nephron cells. In the rat kidney, a1-Na
+, K+-
ATPase is the predominant catalytic and transporting
unit whereas b and g-subunits seem to have a modulatory
role.44 A study investigating Na+, K+-ATPase activity in
the proximal convoluted tubule found a decrease of Na+,
K+-ATPase activity with aging,45 whereas another study
reported no such eﬀects.46
To determine whether the eﬀects of aging and/or
ET receptor blockade aﬀect intrarenal gene expression
of sodium-regulating proteins, molecular analyses were
performed in renal cortex and medulla. Surprisingly, and
despite the changes in ion excretion, we found that in the
renal cortex and medulla aging per se had no eﬀect
on expression levels of the genes investigated. However,
a down-regulation of aENaC and a1-Na
+, K+-ATPase
gene expression was observed after darusentan treatment
only in the cortex of aged rats; interestingly, this eﬀect
was unrelated to mean arterial pressure, circulating renin,
or ACE activity. The underlying mechanisms for this
regulation are currently unknown but may include
interactions between proteinuria and natriuresis,47
as we have previously shown that ETA receptor blockade
improves age-dependent proteinuria by reversing podo-
cyte injury.11 The beneﬁt of ENaC-inhibition in blacks
with hypertension, who are often resistant to standard
antihypertensive therapy,48 has been most recently
demonstrated.49 Alternatively, mechanisms by which
darusentan aﬀects sodium excretion may include eﬀects
of serum-regulated and glucocorticoid-regulated kinase-1,
which mediates ENaC traﬃcking and is stimulated by
ET-1. This eﬀect of glucocorticoid-regulated kinase-1 is
comparable to that of aldosterone and sensitive to ETA
receptor blockade.50,51 As we detected a down-regulation
of aENaC gene expression after darusentan treatment
only in the cortex and as ENaC subunits are known to be
localized among others in the cortical collecting duct,52
the eﬀects of darusentan might also involve suppression
of ENaC mRNA in the cortical collecting duct. Further-
more, the observed down-regulation of the aENaC gene
is likely to contribute to sodium excretion as the gene
product is rate limiting for the assembly of the mature
ENaC complex.53 Although the data of the present study
using whole kidney tissue of cortex and medulla suggest
the possibility that cortical ENaC and Na+, K+-ATPase
expression may contribute to renal sodium handling in
the aging kidney, the results of the present study are
limited by the fact that only mRNA expression was
investigated and that protein abundance or enzyme
activity might not have been equally aﬀected by
darusentan treatment.
Sodium excretion in the collecting duct via ENaC in
addition to ET-1 is regulated by aldosterone54; however,
other humoral factors such as renin, vasopressin,54 and
nitric oxide (NO)55 also play a role. Regarding NO, we
have previously shown that in the presence of increasing
ET-1 expression in the aging kidney, renal tissue levels of
stable metabolites of NO decrease14 as does basal and
stimulated endothelial NO bioactivity.56 Given that NO is
a potent inhibitor of both ET-157 and also of sodium
reabsorption,55 age-dependent decreases in NO bioactiv-
ity may further reduce sodium excretion, and thereby
aggravate the eﬀect of ET-1 in aged rats. Interestingly,
and in line with what has been shown in humans,58 aging
in the present study was associated with a more than 75%
decrease in renin activity, but not aldosterone plasma
levels. An unexpected result of the present study was the
ﬁnding that ETA receptor blockade increased aldosterone
plasma levels in aged but not in young rats. This eﬀect of
darusentan could be related to selective ETB receptor
stimulation in the rat59,60 and, possibly, the eﬀects of the
drug on sodium excretion might have been even more
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pronounced if aldosterone levels had been unaﬀected. An
expected rise in blood pressure with increased aldosterone
levels may, however, be prevented by ETA receptor
blockade.61 Additionally, ET-mediated increases in aldo-
sterone secretion could be responsible for the increased
potassium excretion observed in darusentan-treated aged
animals.
CONCLUSIONS
The ﬁndings of the present study indicate that aged
in otherwise healthy and normotensive rats is associated
with changes in ion secretion and plasma renin activity. In
aged but not in young rats, ion excretion and aldosterone
plasma levels increased after 4 weeks of ETA receptor
blockade. These changes were associated with the
inhibition of gene expression of 2 important regulators
of sodium homeostasis in the renal cortex, aENaC and
a1-Na
+, K+-ATPase. These ﬁndings may be of possible
relevance for the pathogenesis of sodium sensitivity,
which increases with aging and is associated with an
activation of the ET system in animals and humans.
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